The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE^-/- mice by blocking monocyte/macrophage activation.

ABSTRACT:

Objective

The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) are secreted by the gut after food intake leading to pancreatic insulin secretion and glucose lowering. Beyond its role in glucose control, GLP-1 was found in mice and men to beneficially modulate the process of atherosclerosis, which has been linked to improved cardiovascular outcome of patients with diabetes at high cardiovascular risk treated with GLP-1 receptor agonists. However, little is known on the role of the other main incretin in the cardiovascular system. The aim of this study was to characterize GIP in atherosclerotic cardiovascular disease.

Methods and results

Serum concentrations of GIP were assessed in 731 patients who presented for elective coro

SUBMITTER: Kahles F 

PROVIDER: S-EPMC6034034 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature